Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathy MacLean

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2018
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk FeaturesAnna L Godfrey, Peter J Campbell, Cathy MacLean, et al.
Canadian Family Physician Medecin De Famille Canadien|April 16, 2010
Family medicine in 2018Keith D Ogle, Richard Boulé, R Jamie Boyd, et al.
BMJ Open|February 25, 2022
Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trialScott R Garrison, Michael R Kolber, G Michael Allan, et al.
The New England Journal of Medicine|October 11, 2018
Classification and Personalized Prognosis in Myeloproliferative NeoplasmsJacob Grinfeld, Jyoti Nangalia, E Joanna Baxter, et al.
Journal of the American Heart Association|October 9, 2025
Interaction Between Chronotype and the Timing of Antihypertensive Medication on Cardiovascular Events and DeathScott R Garrison, Jeffrey A Bakal, Michael R Kolber, et al.
JAMA|May 12, 2025
Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical TrialScott R Garrison, Jeffrey A Bakal, Michael R Kolber, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2018
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk FeaturesAnna L Godfrey, Peter J Campbell, Cathy MacLean, et al.
Canadian Family Physician Medecin De Famille Canadien|April 16, 2010
Family medicine in 2018Keith D Ogle, Richard Boulé, R Jamie Boyd, et al.
BMJ Open|February 25, 2022
Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trialScott R Garrison, Michael R Kolber, G Michael Allan, et al.
The New England Journal of Medicine|October 11, 2018
Classification and Personalized Prognosis in Myeloproliferative NeoplasmsJacob Grinfeld, Jyoti Nangalia, E Joanna Baxter, et al.
Journal of the American Heart Association|October 9, 2025
Interaction Between Chronotype and the Timing of Antihypertensive Medication on Cardiovascular Events and DeathScott R Garrison, Jeffrey A Bakal, Michael R Kolber, et al.
JAMA|May 12, 2025
Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical TrialScott R Garrison, Jeffrey A Bakal, Michael R Kolber, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Pageof 4